Mira Pharmaceuticals Inc (NASDAQ:MIRA)’s traded shares stood at 0.43 million during the latest session, with the company’s beta value hitting 2.17. At the last check today, the stock’s price was $1.21, to imply an increase of 3.01% or $0.04 in intraday trading. The MIRA share’s 52-week high remains $5.01, putting it -314.05% down since that peak but still an impressive 57.85% since price per share fell to its 52-week low of $0.51. The company has a valuation of $19.96M, with an average of 0.24 million shares in intraday trading volume over the past 10 days and average of 445.69K shares over the past 3 months.
Mira Pharmaceuticals Inc (NASDAQ:MIRA) trade information
After registering a 3.01% upside in the latest session, Mira Pharmaceuticals Inc (MIRA) has traded red over the past five days. The 5-day price performance for the stock is 0.43%, and -19.11% over 30 days. With these gigs, the year-to-date price performance is 5.72%. Short interest in Mira Pharmaceuticals Inc (NASDAQ:MIRA) saw shorts transact 1.26 million shares and set a 0.47 days time to cover.
Mira Pharmaceuticals Inc (MIRA) estimates and forecasts
Looking at statistics comparing Mira Pharmaceuticals Inc share performance against respective industry, we note that the company has underperformed competitors. Mira Pharmaceuticals Inc (MIRA) shares are -43.42% down over the last 6 months, with its year-to-date growth rate lower than industry average at 6.25% against 16.00%.
MIRA Dividends
Mira Pharmaceuticals Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Mira Pharmaceuticals Inc (NASDAQ:MIRA)’s Major holders
Mira Pharmaceuticals Inc insiders hold 27.21% of total outstanding shares, with institutional holders owning 5.96% of the shares at 8.18% float percentage. In total, 5.96% institutions holds shares in the company.